Ocuphire Pharma, Inc. (REXN) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1159948,
    "name": "Ocuphire Pharma, Inc.",
    "stock_name": "Ocuphire Pharma, Inc.",
    "full_name": "Ocuphire Pharma, Inc.",
    "name_url": "stocks-analysis/ocuphire-pharma-inc",
    "exchange": 210,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "2.23",
    "chg": 0.24,
    "chgp": "12.06%",
    "dir": 1,
    "prev_price": "1.99",
    "mcapval": "83.87",
    "mcap": "Micro Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2305,
    "indexname": "S&P 500",
    "isin": "US67577R1023",
    "curr_date": "Dec 04",
    "curr_time": "",
    "bse_nse_vol": "765.71 k",
    "exc_status": "Active",
    "traded_date": "Dec 04, 2025",
    "traded_date_str": "2025 12 04",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/ocuphire-pharma-inc-1159948-210&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Ocuphire Pharma Hits New 52-Week High of $2.37, Up 25.88%",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/ocuphire-pharma-hits-new-52-week-high-of-237-up-2588-3671545",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/OcuphirePharmaI_priceRelatedfactors_3671545.png",
        "date": "2025-11-04 18:05:09",
        "description": "Ocuphire Pharma, Inc. achieved a new 52-week high of USD 2.37 on November 3, 2025, significantly up from its low of USD 0.65. With a market cap of USD 84 million, the company operates in the Pharmaceuticals & Biotechnology sector, facing challenges reflected in its financial metrics."
      },
      {
        "title": "Ocuphire Pharma Hits New 52-Week High of $2.30, Reflecting Strong Growth",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/ocuphire-pharma-hits-new-52-week-high-of-230-reflecting-strong-growth-3667345",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/OcuphirePharmaI_priceRelatedfactors_3667345.png",
        "date": "2025-11-03 17:18:26",
        "description": "Ocuphire Pharma, Inc. achieved a new 52-week high of USD 2.30 on October 31, 2025, reflecting a strong performance with a one-year gain of 35.29%. The company, categorized as a microcap stock, operates in the Pharmaceuticals & Biotechnology industry and currently faces financial challenges."
      },
      {
        "title": "Ocuphire Pharma Hits New 52-Week High of $2.16, Marking Significant Growth",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/ocuphire-pharma-hits-new-52-week-high-of-216-marking-significant-growth-3604403",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/OcuphirePharmaI_priceRelatedfactors_3604403.png",
        "date": "2025-10-08 17:00:12",
        "description": "Ocuphire Pharma, Inc. achieved a new 52-week high of USD 2.16 on October 7, 2025, significantly up from its 52-week low of USD 0.65. With a market cap of USD 84 million, the company operates at a loss and has a premium price-to-book ratio, reflecting its market dynamics."
      },
      {
        "title": "Ocuphire Pharma Hits New 52-Week High of $2.11, Reflecting Strong Growth",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/ocuphire-pharma-hits-new-52-week-high-of-211-reflecting-strong-growth-3601705",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/OcuphirePharmaI_priceRelatedfactors_3601705.png",
        "date": "2025-10-07 22:03:23",
        "description": "Ocuphire Pharma, Inc. has achieved a new 52-week high of USD 2.11, significantly up from its low of USD 0.65. With a market cap of USD 84 million, the company faces challenges, including a negative return on equity and a high price-to-book ratio, reflecting its competitive industry landscape."
      },
      {
        "title": "Ocuphire Pharma Hits New 52-Week High of $1.92, Signaling Growth Potential",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/ocuphire-pharma-hits-new-52-week-high-of-192-signaling-growth-potential-3595688",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/OcuphirePharmaI_priceRelatedfactors_3595688.png",
        "date": "2025-10-06 17:43:51",
        "description": "Ocuphire Pharma, Inc. has achieved a new 52-week high of USD 1.92, significantly up from its low of USD 0.65, reflecting a year-over-year performance of 10.59%. The company, with a market cap of USD 84 million, faces financial challenges, including a loss-making position and a high debt-to-equity ratio."
      },
      {
        "title": "Ocuphire Pharma Hits New 52-Week High of $1.83",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/ocuphire-pharma-hits-new-52-week-high-of-183-3579401",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/9/OcuphirePharmaI_priceRelatedfactors_3579401.png",
        "date": "2025-09-29 14:33:19",
        "description": "Ocuphire Pharma, Inc. has achieved a new 52-week high of USD 1.83, significantly up from its low of USD 0.65. The company, with a market cap of USD 84 million, faces challenges reflected in its negative return on equity and high price-to-book ratio, amid a competitive market landscape."
      },
      {
        "title": "Ocuphire Pharma Hits New 52-Week High of $1.76, Signaling Growth",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/ocuphire-pharma-hits-new-52-week-high-of-176-signaling-growth-3574526",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/9/OcuphirePharmaI_priceRelatedfactors_3574526.png",
        "date": "2025-09-26 15:17:33",
        "description": "Ocuphire Pharma, Inc. has achieved a new 52-week high of USD 1.76, significantly up from its low of USD 0.65. With a market capitalization of approximately USD 84 million, the company remains in the microcap category, despite ongoing financial challenges and a modest one-year performance compared to broader market indices."
      },
      {
        "title": "Is Ocuphire Pharma, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-ocuphire-pharma-inc-technically-bullish-or-bearish-3548181",
        "imagepath": "",
        "date": "2025-09-20 20:11:32",
        "description": "As of 2 September 2025, the technical trend for Ocuphire Pharma, Inc. has changed from mildly bullish to bullish. The current technical stance is bullish with strong indicators supporting this view. The weekly MACD is bullish, and both the weekly and monthly Bollinger Bands are bullish. Daily moving averages also indicate a bullish trend. The KST is bullish on a weekly basis and mildly bullish monthly, while the OBV shows bullish signals for both time frames. \n\nIn terms of performance, Ocuphire has outperformed the S&P 500 over the past week and month, with returns of 5.67% and 29.57% compared to the S&P 500's 1.05% and 2.33%, respectively. However, the longer-term returns over 1 year, 3 years, and 5 years show underperformance relative to the benchmark...."
      },
      {
        "title": "Is Ocuphire Pharma, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-ocuphire-pharma-inc-overvalued-or-undervalued-3544308",
        "imagepath": "",
        "date": "2025-09-20 18:43:00",
        "description": "As of 8 March 2024, the valuation grade for Ocuphire Pharma, Inc. has moved from attractive to risky, indicating a shift in perception regarding its financial health and future prospects. The company appears to be overvalued based on its current metrics, particularly with a Price to Book Value of 12.23 and an EV to Sales ratio of 2.86, which suggest that investors are paying a premium for the stock despite its negative earnings. Additionally, the company's ROE stands at a staggering -660.22%, highlighting significant financial distress.\n\nIn comparison to its peers, Ocuphire Pharma, Inc. has a worse EV to EBITDA ratio of -1.08, while CytomX Therapeutics, Inc., which is rated very attractive, boasts an EV to EBITDA of 4.6280. Other risky peers like Aquestive Therapeutics, Inc. show even more concerning metrics with an EV to EBITDA of -12.8252. Despite recent stock performance where Ocuphire outperformed the S..."
      }
    ],
    "total": 13,
    "sid": "1159948",
    "stock_news_url": "https://www.marketsmojo.com/news/ocuphire-pharma-inc-1159948"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Ocuphire Pharma Hits New 52-Week High of $2.37, Up 25.88%

2025-11-04 18:05:09

Ocuphire Pharma, Inc. achieved a new 52-week high of USD 2.37 on November 3, 2025, significantly up from its low of USD 0.65. With a market cap of USD 84 million, the company operates in the Pharmaceuticals & Biotechnology sector, facing challenges reflected in its financial metrics.

Ocuphire Pharma Hits New 52-Week High of $2.30, Reflecting Strong Growth

2025-11-03 17:18:26

Ocuphire Pharma, Inc. achieved a new 52-week high of USD 2.30 on October 31, 2025, reflecting a strong performance with a one-year gain of 35.29%. The company, categorized as a microcap stock, operates in the Pharmaceuticals & Biotechnology industry and currently faces financial challenges.

Ocuphire Pharma Hits New 52-Week High of $2.16, Marking Significant Growth

2025-10-08 17:00:12

Ocuphire Pharma, Inc. achieved a new 52-week high of USD 2.16 on October 7, 2025, significantly up from its 52-week low of USD 0.65. With a market cap of USD 84 million, the company operates at a loss and has a premium price-to-book ratio, reflecting its market dynamics.

Ocuphire Pharma Hits New 52-Week High of $2.11, Reflecting Strong Growth

2025-10-07 22:03:23

Ocuphire Pharma, Inc. has achieved a new 52-week high of USD 2.11, significantly up from its low of USD 0.65. With a market cap of USD 84 million, the company faces challenges, including a negative return on equity and a high price-to-book ratio, reflecting its competitive industry landscape.

Ocuphire Pharma Hits New 52-Week High of $1.92, Signaling Growth Potential

2025-10-06 17:43:51

Ocuphire Pharma, Inc. has achieved a new 52-week high of USD 1.92, significantly up from its low of USD 0.65, reflecting a year-over-year performance of 10.59%. The company, with a market cap of USD 84 million, faces financial challenges, including a loss-making position and a high debt-to-equity ratio.

Ocuphire Pharma Hits New 52-Week High of $1.83

2025-09-29 14:33:19

Ocuphire Pharma, Inc. has achieved a new 52-week high of USD 1.83, significantly up from its low of USD 0.65. The company, with a market cap of USD 84 million, faces challenges reflected in its negative return on equity and high price-to-book ratio, amid a competitive market landscape.

Ocuphire Pharma Hits New 52-Week High of $1.76, Signaling Growth

2025-09-26 15:17:33

Ocuphire Pharma, Inc. has achieved a new 52-week high of USD 1.76, significantly up from its low of USD 0.65. With a market capitalization of approximately USD 84 million, the company remains in the microcap category, despite ongoing financial challenges and a modest one-year performance compared to broader market indices.

Is Ocuphire Pharma, Inc. technically bullish or bearish?

2025-09-20 20:11:32

As of 2 September 2025, the technical trend for Ocuphire Pharma, Inc. has changed from mildly bullish to bullish. The current technical stance is bullish with strong indicators supporting this view. The weekly MACD is bullish, and both the weekly and monthly Bollinger Bands are bullish. Daily moving averages also indicate a bullish trend. The KST is bullish on a weekly basis and mildly bullish monthly, while the OBV shows bullish signals for both time frames. In terms of performance, Ocuphire has outperformed the S&P 500 over the past week and month, with returns of 5.67% and 29.57% compared to the S&P 500's 1.05% and 2.33%, respectively. However, the longer-term returns over 1 year, 3 years, and 5 years show underperformance relative to the benchmark....

Is Ocuphire Pharma, Inc. overvalued or undervalued?

2025-09-20 18:43:00

As of 8 March 2024, the valuation grade for Ocuphire Pharma, Inc. has moved from attractive to risky, indicating a shift in perception regarding its financial health and future prospects. The company appears to be overvalued based on its current metrics, particularly with a Price to Book Value of 12.23 and an EV to Sales ratio of 2.86, which suggest that investors are paying a premium for the stock despite its negative earnings. Additionally, the company's ROE stands at a staggering -660.22%, highlighting significant financial distress. In comparison to its peers, Ocuphire Pharma, Inc. has a worse EV to EBITDA ratio of -1.08, while CytomX Therapeutics, Inc., which is rated very attractive, boasts an EV to EBITDA of 4.6280. Other risky peers like Aquestive Therapeutics, Inc. show even more concerning metrics with an EV to EBITDA of -12.8252. Despite recent stock performance where Ocuphire outperformed the S...

View All News